Drug Pipeline

16 drugs associated with Hemophilia A

DrugPhaseSponsor
Apixaban

Apixaban selectively inhibits factor Xa in its free and bound forms, independant of antithrombin III. Apixaban also inhibits prothrominase. These effects prevent the formation of a thrombus.

Phase 1Thomas Jefferson University
Kcentra

Coagulation factor VII exogenous protein; Vitamin K-dependent protein S exogenous protein; Vitamin K-dependent protein C exogenous protein; Coagulation factor IX exogenous protein; Thrombin exogenous protein

Phase 1Thomas Jefferson University
NNC 0128-0000-2011
Phase 1Novo Nordisk A/S
NNC 0128-0000-2021

Tissue factor pathway inhibitor inhibitor

Phase 1Novo Nordisk A/S
PF-06741086

Tissue factor pathway inhibitor inhibitor

Phase 1Pfizer
Alta

L-Alturonic Acid is a carbohydrate acid derivative.

phase1_2BEL STAR S A
VGB-R04
Phase 2Shanghai Vitalgen BioPharma Co., Ltd.
AFFINE
Phase 3
aPCC
Phase 3Hoffmann-La Roche
Emicizumab

HEMLIBRA bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.

Phase 3Hoffmann-La Roche
GreenGene™ F
Phase 3Green Cross Corporation
rFVIIa
Phase 3Hoffmann-La Roche
rFVIIIFc
Phase 3Bioverativ Therapeutics Inc.
TRM-201 (Rofecoxib)

Cyclooxygenase-2 inhibitor

Phase 3Tremeau Pharmceuticals, Inc.
Alprolix

Coagulation factor IX exogenous protein

unknownSwedish Orphan Biovitrum
Desmopressin

Upon binding of desmopressin to V2 receptors in the basolateral membrane of the cells of the distal tubule and collecting ducts of the nephron, adenylyl cyclase is stimulated. The resulting intracellular cascades in the collecting duct lead to increased rate of insertion of water channels, called aquaporins, into the lumenal membrane and enhanced the permeability of the membrane to water.

unknownGroupe Maladies hémorragiques de Bretagne